Squarepoint
SLS icon

Squarepoint’s SELLAS Life Sciences SLS Stock Holding History

Squarepoint’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-130,100
Closed -$141K – 5006
2025
Q1 		$141K Buy
+130,100
New +$154K ﹤0.01% 4129
2024
Q4 		– Sell
-16,900
Closed -$21.1K – 5463
2024
Q3 		$21.1K Buy
+16,900
New +$20.7K ﹤0.01% 4021

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Squarepoint's SLS Position: Q1 2026 in Review

Squarepoint increased its SELLAS Life Sciences (SLS) stake by 463% in Q1 2026, buying an estimated $275K and bringing the position to 74,751 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Squarepoint first reported a position in SLS in Q2 2017 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Squarepoint held 74,751 shares of SELLAS Life Sciences worth $316K as of Q1 2026.
  • Squarepoint bought 61,466 SELLAS Life Sciences shares in Q1 2026, an estimated $275K.
  • SELLAS Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3664 holding.
  • Squarepoint first reported a position in SELLAS Life Sciences in Q2 2017 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.